1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Another NASH Failure: Gilead’s Hits Keep Coming

 
• By Mary Jo Laffler

The failure of the STELLAR-3 trial of selonsertib had been widely anticipated following the failure in a sicker population in STELLAR-4.

Bright, blue green wave breaks on body boarder and sends red board flying at the Wedge, Newport Beach. - Image
Another wave of disappointment for Gilead

Gilead Sciences Inc.’s latest failure in non-alcoholic steatohepatitis (NASH) came as little surprise given the drug’s disappointing performance in its first Phase III trial, but it does raise the pressure on Gilead’s other NASH drugs and confuse the understanding about anti-fibrotics in NASH.

The company announced on 25 April that in the Phase III STELLAR-3 trial, selonsertib did not meet the prespecified week...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

J&J’s Trispecific Antibody For Myeloma Offers Improved Safety, Potency Over Bispecifics

 
• By Alaric DeArment

The drugmaker presented data from its Phase I study of JNJ-79635322 at ASCO and EHA showing a 100% response rate in BCMA- and GPRC5D-naïve patients.

ASCO: Pushing The Frontiers Of ADCs

 
• By Mary Jo Laffler

Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.

Skyhawk Looks To Soar With Huntington’s Hope

 
• By Kevin Grogan

Oral RNA splicing modulator has gone into a Phase II/III trial

Scholar Rock Shows Muscle-Building PoC In Obesity

 
• By Jessica Merrill

The company said it intends to maintain a focus on rare neuromuscular disease with apitegromab but could consider partnering in obesity.

More from R&D

Spyre Takes Aim At Roche And J&J In Inflammatory Diseases

 
• By Andrew McConaghie

The US firm was already looking to compete in ulcerative colitis, but now expands its ambitions by moving into rheumatoid arthritis as well.

Ireland’s Got Biopharma Talent To Keep Leading The Pack

 
• By Kevin Grogan

The country’s life sciences investment head tells Scrip that it is business as usual for the sector despite the rumblings from across the Atlantic.

Draig Is All Fired Up To Transform Neuropsychiatric Field

 
• By Kevin Grogan

Wales-based group launches with $140m series A.